Swedish oncology firm Elekta of Stockholm reported that demand for its clinical products and services remained strong in the first three months of its 2011 fiscal year (end-July 31).
Net sales increased 16% to 1.6 billion kronor ($230 million U.S.), compared with 1.4 billion kronor ($201 million U.S.) in the first quarter of fiscal 2010. Operating profit rose to 153 million kronor ($22 million U.S.), compared with 89 million kronor ($12.4 million U.S.) in the same period last year.
The company's acquisition of Resonant Medical has added new image guidance products such as the Clarity soft-tissue visualization software to its portfolio, as well as research and development resources in oncology imaging, Elekta said. The company has also enjoyed high demand for its Leksell Gamma Knife Perfexion.
Elekta holds to its financial outlook for net sales growth of more than 10% and operating profit of more than 15% in fiscal 2011.
Related Reading
Elekta opens South Korean office, September 2, 2010
Elekta wins Australian contract, August 19, 2010
Elekta brings Perfexion to Hawaii, August 16, 2010
Elekta gets CE Mark for iViewC, August 5, 2010
Elekta donates to ASRT scholarships, July 22, 2010
Copyright © 2010 AuntMinnie.com
